Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
about
Sulfonylurea versus metformin monotherapy in patients with type 2 diabetes: a Cochrane systematic review and meta-analysis of randomized clinical trials and trial sequential analysisComparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinationsManagement of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).Use of metformin in the setting of mild-to-moderate renal insufficiencyMolecular mechanism of action of metformin: old or new insights?Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusTargeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitusA Narrative Review of Diabetes Intervention Studies to Explore Diabetes Care Opportunities for PharmacistsClinically and pharmacologically relevant interactions of antidiabetic drugsFilling the Knowledge Gap in Diabetes Management During Ramadan: the Evolving Role of Trial EvidenceThe clinical application of linagliptin in AsiansGlycemic variability and glycemic control in the acutely ill cardiac patientType 2 diabetes in East Asians: similarities and differences with populations in Europe and the United StatesInsulin initiation in patients with type 2 diabetes mellitus: treatment guidelines, clinical evidence and patterns of use of basal vs premixed insulin analoguesTreating the elderly diabetic patient: special considerationsCardiovascular importance of hyperglycemia and hypoglycemiaA critical review of diabetes, glycemic control, and dental implant therapyCommon standards of basal insulin titration in type 2 diabetesClinical utility in the treatment of type 2 diabetes with the saxagliptin/metformin fixed combinationUse of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerationsClinical Effectiveness of Liraglutide in Type 2 Diabetes Treatment in the Real-World Setting: A Systematic Literature ReviewRole of bile acid sequestrants in the treatment of type 2 diabetesA combined analysis of 48 type 2 diabetes genetic risk variants shows no discriminative value to predict time to first prescription of a glucose lowering drug in Danish patients with screen detected type 2 diabetesThe study to understand the genetics of the acute response to metformin and glipizide in humans (SUGAR-MGH): design of a pharmacogenetic resource for type 2 diabetesThe Efficacy and Safety of Chinese Herbal Medicine Jinlida as Add-On Medication in Type 2 Diabetes Patients Ineffectively Managed by Metformin Monotherapy: A Double-Blind, Randomized, Placebo-Controlled, Multicenter TrialConsensus report: the current role of self-monitoring of blood glucose in non-insulin-treated type 2 diabetesCardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetesThe management of type 2 diabetic patients with hypoglycaemic agentsExenatide once weekly: opportunities in the primary care setting.Efficacy and tolerability of exenatide once weekly versus sitagliptin in patients with type 2 diabetes mellitus: a retrospective analysis of pooled clinical trial data.Diabetes mellitus type 2 and other chronic non-communicable diseases in the central region, Saudi Arabia (Riyadh cohort 2): a decade of an epidemic.Review of innovations in digital health technology to promote weight control.Optimal therapy of type 2 diabetes: a controversial challengeChallenges in achieving optimal glycemic control in type 2 diabetes patients with declining renal function: The Southeast Asia perspectiveEvidence-based clinical use of insulin premixturesRegular insulin, rather than rapid-acting insulin, is a suitable choice for premeal bolus insulin in lean patients with type 2 diabetes mellitus.Insulin degludec compared with insulin glargine in insulin-naïve patients with type 2 diabetes: A 26-week, randomized, controlled, Pan-Asian, treat-to-target trial.Impact of hypoglycemia on patients with type 2 diabetes mellitus and their quality of life, work productivity, and medication adherence.Structured self-monitoring of blood glucose reduces glycated hemoglobin in insulin-treated diabetes.
P2860
Q22241119-8E4C1118-466E-44F0-BA28-934A761DD514Q22241134-9A3EF194-A142-4861-92F1-E1C4B3363AB8Q22241288-B46D9F3F-B7A0-498C-91F3-B36968054B42Q22241290-DF513BBB-549E-4064-A3E6-65458150B16EQ22252798-5B7191F9-7ECB-4715-BAE0-F560925236C5Q24186667-E7F45480-89D3-4BB9-8953-C1AC66A28BFAQ24202505-C8851A62-2566-44C1-8B24-D786DE016919Q24236456-CB1A2603-8C9E-4167-A7DB-594B91DC5CB5Q26744229-AD4D9FBC-6571-4F61-893D-B8161FEAFDABQ26752468-0B91B8DE-F6C8-49E5-909D-9AF35BB74CBFQ26752669-808FE413-3036-4E2B-8977-FFB0EFB68DFBQ26781942-ABE3AAFC-4E00-4EC0-93DD-D6CF7E8C0258Q26821994-7A1D1466-E3D2-440D-AFCF-62111AC8E871Q26859746-67345B9F-743B-4E4D-AEE6-876424EBAAF5Q26861313-3167D0C0-F3BF-4364-A579-64D524DEE99DQ26995176-6818B78B-BECF-4FA4-9300-777FAE817177Q26999390-F6B18A35-5518-47D9-8D30-C342AF142DE4Q27006805-A85F8B4C-4989-4FAD-8313-A68547811BE3Q27009355-7CEFA980-FD3F-4D53-B405-02A58EFC56ACQ27026211-02E151F2-0969-4107-B417-D320248FB340Q28072205-D2E052E7-E971-470C-B0F9-7B2D91B51EEAQ28079191-174785BA-CEBA-43D6-B07F-1C630277855FQ28236411-72DACB91-D907-4BA6-A74C-693CA2F6F884Q28542553-334E7C9B-F8F2-4DDE-BFF3-04D9A8BB867DQ28545045-06AFC966-013A-4BD1-A742-EF8FDF256B04Q28548552-AC0F4945-A083-445F-9B73-D784281088E8Q28732681-3BC38C2B-7474-4154-BB98-5CD139603CE8Q28741419-EF5C6C64-E95F-4264-8656-4EB80498E965Q30417363-A3F969C0-6B8B-4F63-9D5B-CF8A49CE696AQ30431639-31CFA942-EE43-468E-AB19-46284F04B43CQ30643065-AA173B65-0D5C-445B-8421-8F8FF071E787Q31019010-D9DCCBBC-086F-4182-B45E-D660E38083B4Q33440728-19663351-58F6-45DF-8BAA-0A93B81C5E7AQ33577712-9941E5A6-1773-413B-BB81-B7685F514D3DQ33587783-683F21A0-31FD-4294-9A25-022114AB7B18Q33591271-211D54B0-1FAF-4338-A4F8-1679D455FB2EQ33603482-D8025E5F-E054-4249-A066-099BD0877CA1Q33607759-B651677D-18C7-4EF0-9AB1-E4136B598550Q33610427-1A7AFEC5-CEE1-435E-BFDB-F94866C2B0C6Q33628249-557DD96A-C8DA-464E-868E-39532F8D340A
P2860
Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Statement by an American Assoc ...... lgorithm for glycemic control.
@en
Statement by an American Assoc ...... lgorithm for glycemic control.
@nl
type
label
Statement by an American Assoc ...... lgorithm for glycemic control.
@en
Statement by an American Assoc ...... lgorithm for glycemic control.
@nl
prefLabel
Statement by an American Assoc ...... lgorithm for glycemic control.
@en
Statement by an American Assoc ...... lgorithm for glycemic control.
@nl
P2093
P356
P1433
P1476
Statement by an American Assoc ...... lgorithm for glycemic control.
@en
P2093
Alan J Garber
Daniel Einhorn
Edward S Horton
Etie S Moghissi
George Grunberger
Harold Lebovitz
Helena W Rodbard
Jaime A Davidson
Paul S Jellinger
Philip Levy
P304
P356
10.4158/EP.15.6.540
P577
2009-09-01T00:00:00Z